Pharmaceutical Market Europe • June 2023 • 34-36
APPOINTMENTS
Kite Pharma
Cindy Perettie
Kite Pharma has appointed Cindy Perettie as executive vice president. Perettie brings extensive experience in oncology, as well as 20 years in leadership roles to her new position. Most recently, she was head of Roche’s Molecular Lab Solutions, where she oversaw the company’s PCR and sequencing business. Prior to that, she was chief executive officer at Foundation Medicine. Before joining Foundation Medicine, Perettie was head of global oncology strategy at Roche’s oncology unit, where she led one of the largest global oncology portfolios in the industry. In 2012, Perettie joined Sarah Cannon Research Institute as president of global development innovations, where she gained valuable insights into the day-to-day care of people living with cancer. She started her career at Johns Hopkins University as a senior research associate. Perettie joins Kite to oversee the company’s cell therapy unit.
Vicinitas Therapeutics
Christian Hofmann
Vicinitas Therapeutics has appointed Christian Hofmann as chief executive officer and a member of the board of directors. Hofmann brings over two decades of experience to the role and joins Vicinitas from Lycia Therapeutics, where he was chief business officer. Prior to this, Hofmann was a member of the partnering group at Roche/Genentech and held roles at several start-ups and Roche Diagnostics.
Immodulon
Gertjan Bartlema
Immodulon has appointed Gertjan Bartlema as chief executive officer. Bartlema joins the company with over 25 years of industry experience in finance, business development and operations. He was most recently CEO at Vico Therapeutics BV. Prior to this, Bartlema spent 12 years at Celgene, where he started as part of its initial European management team. He began his career at Amgen in various roles.
Veranova
Mike Riley
Veranova has appointed Mike Riley as chief executive officer. Riley has over 25 years of professional experience, nearly 19 of which have been spent in the pharmaceutical contract development and manufacturing operations industry. He was most recently president of biotherapeutics at Catalent Pharma Solutions, having held roles of increasing responsibility since joining the company in 2004 as director, business development.
Amphista Therapeutics
Louise Modis
Amphista Therapeutics has appointed Louise Modis as chief scientific officer. Modis has over 20 years of experience in research and development and joins Amphista from Mogrify, where she was CSO. Previously, Modis was vice president and immunology research unit head and sponsor of the immunology network at GSK and held scientific leadership roles at Boehringer Ingelheim and Millennium Pharmaceuticals.
Eterna Therapeutics
Megan Yung
Eterna Therapeutics has appointed Megan Yung as chief strategy officer and general counsel. Yung joins the company from SQZ Biotechnologies, where she served as deputy general counsel and vice president, head of intellectual property. Prior to SQZ, Yung held in-house counsel positions where she served as a key member of the deal teams, and as chief counsel on all litigation, including intellectual property and class action law suits.
The European Laboratory Research & Innovation Group UK
Nick Clare
The European Laboratory Research & Innovation Group UK has appointed Nick Clare to its board as vendor strategy work group lead. Clare is currently regional sales manager (head of Europe) at Synthego and was elected to sit on the general committee of ELRIG in 2021 to support the organisation’s networking work group. Prior to this, he worked as a scientist and lab head in research and development.
Curve Therapeutics
Julian Downward
Curve Therapeutics has appointed Julian Downward to its scientific advisory board. Downward holds over 35 years of research experience and is currently associate research director at the Francis Crick Institute in London. He was also previously team leader at the Institute of Cancer Research, associate director at Cancer Research UK from 2005 to 2015 and executive chairman at the British Association for Cancer Research.
Curve Therapeutics
Steven Benkovic
Curve Therapeutics has appointed Steven Benkovic to its scientific advisory board. Benkovic, who is currently Evan Pugh professor and Eberly chair in chemistry at Penn State University, is known for his contributions in chemical biology that have shaped the understanding of biological processes. He joined the chemistry department at Penn in 1965 and was elected to the US National Academy of Sciences in 1985.
ABPI
Jessamy Baird
The Association of the British Pharmaceutical Industry (ABPI) has appointed Jessamy Baird as vice president elect. Since beginning her career in healthcare research and health economics, Baird has worked in roles that range across the pharmaceutical industry, academia and the NHS, and is currently managing director/country lead at Sanofi UK and Ireland. Her prior role within the company was director of market access, UKIE, where she supported national and local healthcare access for patients to Sanofi medicines and vaccines. Before joining Sanofi in 2015, she worked at Eli Lilly in a range of director roles covering real-world evidence, market access strategy and health technology appraisal across Australia, Canada, Europe and Japan. In her new role at the ABPI, Baird will join and support ABPI president elect Susan Rienow, UK managing director and country president of Pfizer.
Vaccentis AG
Ingrid Rauter
Vaccentis AG has appointed Ingrid Rauter as head of research and development and chief medical officer. Rauter has over ten years of experience in leading global research and development programmes for pipeline and marketing products. She joins the company from her most recent role at Amgen, where she has been serving as global medical affairs asset lead early inflammation pipeline.
Curve Therapeutics
Monica Ermann
Curve Therapeutics has appointed Monica Ermann as vice president drug discovery. Ermann has over two decades of experience in drug discovery and joins Curve from Exscientia, where she held the position of director chemical biology. Prior to this, Ermann spent 20 years at Evotec, where she led multiple hit-to-lead research programmes in a broad range of disease areas, working with pharma partners and academic collaborators.
Vir Biotechnology
Jeff Calcagno
Vir Biotechnology has appointed Jeff Calcagno as executive vice president and chief business officer. Calcagno joins the company from Johnson & Johnson, where he spent more than 12 years holding leadership roles of increasing responsibility within all three divisions of J&J Innovation, including as global transactions lead for infectious diseases and vaccines and as head of JLABS Bay Area.
Charnwood Molecular
Francesca Sadler
Charnwood Molecular has appointed Francesca Sadler as chief commercial officer. Sadler has over 20 years of experience in commercial experience in the discovery and development CRO field, following a career that includes several senior roles at Cyprotex, Aptuit and Charles River Discovery. She joins Charnwood Molecular from her most recent role as senior vice president commercial at Eurofins Discovery.
Sandoz
Shamiram Feinglass
Sandoz has appointed Shamiram Feinglass to its board of directors. Feinglass was most recently chief medical officer for life sciences and diagnostics and vice president global medical affairs and policy, life sciences and diagnostics at Danaher. She is also a board member of the Research and Innovation Advisory Board at Children's National Medical Center and a fellow of the Aspen Institute Global Leadership Network.
Sandoz
Aarti Shah
Sandoz has appointed Aarti Shah to its board of directors. Shah was previously chief information and digital officer and senior vice president at Eli Lilly from 2016 to 2021, and held other digital and data sciences related roles of increasing responsibility over her 27 years at Lilly, including global brand development leader. She serves as a board member at both NVIDIA Corporation and Northwestern Mutual, both since 2020.
MHRA
Amanda Calvert
The MHRA has appointed Amanda Calvert as non-executive director. Calvert brings decades of experience within the life sciences sector to the role, having worked for ICI, Zeneca and AstraZeneca in a variety of senior operational roles across a wide range of business functions. She founded Quince Consultancy in 2014 and has been serving as its chief executive officer. She is also a non-executive director of The Guinness Partnership.
MHRA
Michael Whitehouse
The MHRA has appointed Michael Whitehouse as non-executive director. Whitehouse, who has also been appointed as audit and risk assurance committee chair of the agency, has decades of experience as an external auditor of central government on behalf of parliament. For 15 years, he was an executive board member of the National Audit Office and he was COO for eight years. He holds a range of non-executive portfolio appointments.
Inizio
Matt Lewis
Inizio has appointed Matt Lewis as global chief artificial and augmented intelligence officer. Lewis has worked for Inizio and its parent companies for the past eight years in a number of senior positions. Prior to joining Inizio, he was global chief data at MEDiSTRAVA and analytics officer at ApotheCom. Most recently, Lewis was global chief medical analytics and innovation officer at Inizio Medical.
Inizio
Paul Hatton
Inizio has appointed Paul Hatton as president of medical analytics and innovation. Hatton brings significant leadership experience and expertise to his new role, having recently served as managing director of both Synaptik and Medical Expressions, part of the Nucleus Global network. Hatton was also previously managing director at MediTech Media, Europe, after joining the company as director of client services.
Envision Pharma Group
Jennifer Costello
Envision Pharma Group has appointed Jennifer Costello as chief medical officer. Costello brings over 20 years of experience across the healthcare sector to the role. She has previously held multiple leadership positions in global medical affairs and publications, and has also spent 16 years as a practising clinical pharmacist. Joining from Bristol Myers Squib, she recently led cardiovascular patient advocacy across its portfolio.
Envision Pharma Group
Mike Glover
Envision Pharma Group has appointed Mike Glover as senior vice president, payer and HTA solutions. Glover brings diverse and extensive experience to the role and joins the company from GSK, where he served as vice president, head of global access and pricing strategy. Prior to this, he held leadership positions of increasing responsibility there and at Sanofi and Bristol Myers Squibb. He has also worked at Celgene, Pfizer and AstraZeneca.
SAY Communications
Surinder Maan
SAY Communications has appointed Surinder Maan as associate director. Maan brings over 20 years of experience in healthcare communications to the role. She was recently external communications manager at LifeArc. Prior to this, she was senior account director at Virgo Health, and has also worked at Publicis Resolute, Roche, Hanover Communications, ViiV Healthcare and GSK.
90TEN
Meghan Kelly
90TEN has appointed Meghan Kelly as scientific director. Having dedicated her entire education to science and healthcare, Kelly has several years of experience as a science writer at Science Diffusion Ltd, as well as an associate medical writer at Iceberg Medical. She was most recently senior medical director, also at 90TEN, having originally joined the agency as associate medical writer at the beginning of 2019.
Bedrock Healthcare Communications
Alice Waterhouse
Bedrock Healthcare Communications has appointed Alice Waterhouse as scientific director. Waterhouse has a decade of experience in healthcare communications and originally the agency last year as associate scientific director. Prior to this, she was associate scientific director at LiNK Health Group and senior medical writer at Chameleon Communications International and Havas Lynx Group.
Saatchi & Saatchi Wellness
Madhuri Fletcher
Saatchi & Saatchi Wellness has appointed Madhuri Fletcher as senior vice president of medical strategy. Fletcher brings extensive experience to the role, having worked across a wide variety of therapeutic areas. She joins from Publicis Health sister agency Heartbeat, where she has been leading medical strategy for over five years. Prior to this, she was vice president, medical director, at Harrison and Star.
Saatchi & Saatchi Wellness
Michelle Rowley
Saatchi & Saatchi Wellness has appointed Michelle Rowley as senior vice president of consumer brand strategy. Rowley joins the agency with extensive experience leading strategic thinking for wellness brands, including Cetaphil, Differin, ACUVUE, Purina, Pantene and DePuy Synthes. She was most recently senior vice president, group planning director, at Deutsch NY, and has held roles at Deep Focus and Grey.
Saatchi & Saatchi Wellness
Noel Castro
Saatchi & Saatchi Wellness has appointed Noel Castro as executive vice president of HCP brand strategy. Castro brings extensive experience to the role, having worked across a wide range of therapeutic areas, including oncology, rare disease, obesity, epilepsy and vaccinations. He was previously chief creative officer and managing director at Havas, and has also founded and run his own company.
90TEN
Airyana Anderson
90TEN has appointed Airyana Anderson as account executive. Anderson originally joined the agency at the beginning of 2022 as associate account executive, marking her first step into a healthcare communications career. Anderson has over two years’ worth of experience within the marketing, communication and event management field, as seen in her previous role as marketing and event coordinator at MarineMax.
90TEN
Silvia Garbayo Muriel
90TEN has appointed Silvia Garbayo Muriel as account executive. Before embarking on a new career in healthcare at the company in 2022, Muriel’s expertise included project design, data analysis, including both scientific, marketing and sales, as well as project management. She began her healthcare communications career with 90TEN less than a year ago as an assistant account executive.